-
Centralized procurement of generic drugs on the market allows patients to use "reasonable drugs"
Time of Update: 2021-06-17
Zhang Lan, Director of the Department of Pharmacy, Xuanwu Hospital, Capital Medical University : Compared with the original drugs in the 14 centralized procurements we evaluated, there was no significant difference (statistical difference) in clinical effects and use (statistical differences), for example, in the treatment of virality.
-
Harbin Pharmaceutical Group: Simvastatin tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-06-17
② for pure hypercholesterolemia patients with homozygous familial, when diet and non-diet is not ideal, simvastatin can be used to reduce elevated total cholesterol, LDL cholesterol and apolipoprotein B .
② Reduce the risk of death from coronary heart disease and non-fatal myocardial infarction .
-
Pfizer and others go forward and continue AD research and development stagnant, can Bojian Aducanumab stand out?
Time of Update: 2021-06-17
Similarly, in the face of such urgent patient demand and market vacancies, in addition to the approval of the ninth phase one developed by Green Valley Pharmaceuticals, currently domestic companies including Hengrui, Dongyang Sunshine, Hisun and other companies have joined the track.
-
Blowouts in batches, stratification and classification have appeared, and the collection rules for high-value medical consumables continue to iterate
Time of Update: 2021-06-17
Medical Network, June 8th, June 4th, the National Medical Insurance Administration, the National Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry o
-
Centralized procurement "big killer": the Guangxi version of the medical insurance balance retention policy is here!
Time of Update: 2021-06-17
On January 15 this year, according to the "Chongqing Daily" report, a total of 157 medical institutions in Chongqing participated in the first batch of national centralized procurement of 25 selected drugs and medical insurance fund balance retention assessment, of which 102 medical institutions passed the assessment and the balance medical insurance fund was 61,974,400 Yuan .
-
18 pharmaceutical stocks with a market value of 100 billion yuan appeared!
Time of Update: 2021-06-17
In addition, 7 companies including Wantai Biotech, Kanglong Chemical, and Tongce Medical have achieved a market value of 100 billion yuan, and 6 such as Watson Biotechnology and Huaxi Biotechnology have increased by more than 50% this year.
-
215 pharmacies closed for rectification in one place
Time of Update: 2021-06-17
In addition to not strictly implementing the drug purchase information registration and reporting system, the municipal supervision department also found that some pharmacies did not implement the prevention and control measures such as "requiring customers to take body temperature and wear masks" .
-
Fierce competition among leading companies in the diabetes drug market for new drug development
Time of Update: 2021-06-17
The expansion of indications has become a market growth point In December 2019, Sanofi announced that it would stop research on new drugs for the treatment of diabetes and cardiovascular diseases, and shift to the field of autoimmunity and tumor treatment .
-
National Health Commission: 3,070 critically ill newborn care centers have been established nationwide
Time of Update: 2021-06-17
Medical Network News, June 9th, 8th, the State Information Office held a press conference. Song Li, spokesperson for the National Health Commission, said that the health of minors is an important fo
-
Nearly 20 original research drugs have encountered patent challenges!
Time of Update: 2021-06-17
Chongqing Yaoyou Pharmaceutical challenged the patent of this pharmaceutical preparation, and the State Intellectual Property Office made a complete invalidation decision on ZL200680007187.
Chongqing Yaoyou Pharmaceutical challenged the patent of this pharmaceutical preparation, and the State Intellectual Property Office made a complete invalidation decision on ZL200680007187.
-
Samsung Pharmaceuticals and GemVax submit new drug Phase III trial results
Time of Update: 2021-06-17
In 16 hospitals in South Korea (including Severance Hospital), the RIAVAX Phase III clinical trial was conducted with gemcitabine/capecitabine to study the safety and efficacy in 148 patients with locally advanced and metastatic pancreatic cancer Sex .
-
National Development and Reform Commission: Regional medical center construction will cover all provinces by the end of next year
Time of Update: 2021-06-17
On June 8th, regarding the construction of regional medical centers, Sun Zhicheng, head of the Department of Social Development of the National Development and Reform Commission, stated in Beijing on the 7th that 12 more provinces in the central and western regions with relatively short supply of high-quality medical resources will be included in the pilot program this year; By the end of next year, the construction of regional medical centers shall be covered in all provinces .
-
The largest GPO!
Time of Update: 2021-06-17
In terms of centralized procurement and bargaining methods, the "Document" stipulates that the first category of drugs: the selected varieties purchased by the state and this city in a large amount shall be implemented at the selected prices and related regulations .
-
Can't there be two medical insurance shops within 150 meters?
Time of Update: 2021-06-17
Zhang, who has been operating a pharmacy in the local area for 6 years and has not yet been approved for designated medical insurance, said: "The access to medical insurance designated pharmacies of 9 counties and 3 districts in Linyi City is limited to 150 radius distances only in Lanling County .
-
Deepen the reform of public hospitals and promote the improvement of the medical service capabilities of primary hospitals
Time of Update: 2021-06-17
In response to the national health care reform "strong grassroots" policy call, national health Health Management Institute under the National Health Committee of Hospital Health Committee of Medical Administration Authority Instructions, Hui cause support, five years continued to carry out a "set sail in the county" - County-level public hospital hospital management and clinical key specialty capacity building project .
-
National Medical Insurance Administration: "Zero Tolerance" for Medical Insurance Fraud
Time of Update: 2021-06-17
Medical Network, June 7th, a reporter learned from the China National Medical Insurance Administration on the 6th that the bureau will soon inform the National Medical Insurance System of Anhui Province’s investigation of fraudulent insurance cases in Taihe County, and require medical insurance departments at all levels to deal with medical insurance fraud fraud.
-
The 2020 national "medical insurance bill" is released!
Time of Update: 2021-06-17
4% of the year’s GDP; the total expenditure of the national basic medical insurance fund (including maternity insurance) was 21,032 billion yuan, a year-on-year increase of 1.
-
The per capita financial subsidy standard for resident medical insurance is not less than 580 yuan per person per year
Time of Update: 2021-06-17
The "Notice" proposes to promote the reform of medical insurance payment methods, normalize the centralized procurement of drugs , strengthen the supervision of medical insurance funds, and continuously improve the efficiency of the use of residents' medical insurance funds .
-
Zhengda Tianqing is showing off!
Time of Update: 2021-06-17
Figure 1: The status of new drugs and generic products declared by Nanjing Chia Tai Tianqing since 2021 Source: CDE official website In March 2019, Bayer's tedizolamide phosphate tablets and injections were approved for marketing by NMPA, and the approved indications are acute skin and skin tissue infections in adults caused by gram-positive bacteria .
-
Xinlitai hypertension drug allisartan medoxomil and indapamide sustained-release tablets received clinical approval
Time of Update: 2021-06-17
Today, Xinlitai issued an announcement stating that the company received the "Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration, and agreed to carry out clinical trials for allisartan medoxomil indapamide sustained-release tablets .
1-type antihypertensive drug Xin Litan (alisartan medoxomil tablets) to cover different market segments .
